Ixaka Ltd.
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Subsidiary
- Established
- 2015-01-01
- Employees
- 51
- Market Cap
- -
- Website
- http://www.ixaka.com
The Efficacy and Safety of REX-001 to Treat Ischemic Ulcers in Subjects With CLI Rutherford Category 5 and DM
Phase 3
Terminated
- Conditions
- Peripheral Arterial Disease (PAD)Diabetes Mellitus (DM)Diabetes Mellitus, Type 1Diabetes Mellitus, Type 2Cardiovascular DiseaseCritical Limb Ischemia (CLI)
- Interventions
- Drug: Placebo
- First Posted Date
- 2017-06-02
- Last Posted Date
- 2023-03-16
- Lead Sponsor
- Ixaka Ltd
- Target Recruit Count
- 49
- Registration Number
- NCT03174522
- Locations
- 🇪🇸
Hospital Regional Universitario, Málaga, Spain
🇵🇹Centro Hospitalar de São João, Porto, Portugal
🇪🇸Hospital Universitario Puerta del Mar, Cadiz, Spain
The Efficacy and Safety of REX-001 to Treat Ischemic Rest Pain in Subjects With CLI Rutherford Category 4 and DM
Phase 3
Terminated
- Conditions
- Peripheral Arterial Disease (PAD)Diabetes Mellitus, Type 1Critical Limb Ischemia (CLI)Diabetes Mellitus (DM)Diabetes Mellitus, Type 2Cardiovascular Disease
- Interventions
- Drug: Placebo
- First Posted Date
- 2017-04-12
- Last Posted Date
- 2021-05-07
- Lead Sponsor
- Ixaka Ltd
- Target Recruit Count
- 3
- Registration Number
- NCT03111238
- Locations
- 🇪🇸
First site: Hospital Universitario Reina SofÃa, Córdoba, Spain
🇪🇸Hospital General Universitario Morales Meseguer, Murcia, Spain
🇨🇿Fakultnà nemocnice Ostrava, Ostrava, Czechia
© Copyright 2025. All Rights Reserved by MedPath